Influenza viruses are negative-sense, single-stranded ribonucleic acid (RNA) viruses of the family Orthomyxoviridae whose capacity for rapid antigenic change drives annual epidemic cycles and the periodic pandemics that have caused catastrophic global mortality. Understanding the structural proteins targeted by antivirals and the replication steps they interrupt provides the conceptual framework for rational drug selection across this pharmacologically diverse class.
Viral Structure and Antigenic Variation. Influenza A and B viruses are enveloped viruses whose surface glycoproteins hemagglutinin (HA) and neuraminidase (NA) are the principal antigenic determinants and the targets of both vaccine-induced immunity and antiviral drugs. Hemagglutinin mediates viral attachment to sialic acid residues on respiratory epithelial cells and facilitates endosomal membrane fusion following receptor-mediated endocytosis. Neuraminidase cleaves sialic acid linkages, enabling release of newly assembled virions from infected cells and preventing viral aggregation at the cell surface. Influenza A viruses are further classified by HA subtype (H1 through H18) and NA subtype (N1 through N11), with influenza A/H1N1 (H1N1) and influenza A/H3N2 (H3N2) being the subtypes currently circulating in humans. Antigenic drift, the gradual accumulation of point mutations in HA and NA driven by immune selection pressure, necessitates annual vaccine reformulation. Antigenic shift, the reassortment of gene segments between human and animal influenza strains, produces novel subtypes with pandemic potential because pre-existing population immunity is absent.1
Replication Cycle and Antiviral Targets. Following receptor binding and endocytosis, the low pH of the endosome triggers conformational change in HA, initiating membrane fusion and release of viral ribonucleoprotein (vRNP) complexes into the cytoplasm. The vRNP complexes are transported to the nucleus, where the viral RNA-dependent RNA polymerase (RdRp) complex — comprising three subunits designated polymerase basic protein 1 (PB1), polymerase basic protein 2 (PB2), and polymerase acidic protein (PA) — transcribes viral messenger RNA (mRNA) and replicates the viral genome. The PA subunit possesses cap-dependent endonuclease activity, cleaving the 5'-capped primers from host pre-mRNA to initiate viral mRNA synthesis in a process called cap-snatching. Newly synthesized viral proteins and genomic segments are assembled into progeny virions that bud from the apical surface of infected cells, requiring neuraminidase activity to cleave the sialic acid tethers that retain budding virions at the cell surface.2 These three steps — membrane fusion (targeted by older adamantane agents acting on the M2 ion channel), cap-snatching (targeted by baloxavir), and virion release (targeted by neuraminidase inhibitors) — constitute the pharmacological attack points of all currently licensed influenza antivirals.
Rationale and Timing for Antiviral Treatment. The clinical benefit of influenza antivirals is time-dependent in a way that parallels the pharmacodynamics of their viral targets. Viral replication peaks within 24 to 72 hours of symptom onset and declines rapidly thereafter as innate immune responses clear the infection. Treatment initiated within 48 hours of symptom onset reduces illness duration by approximately one to three days and reduces the risk of complications including pneumonia and hospitalization. Treatment initiated after 48 hours provides diminishing benefit in otherwise healthy outpatients but retains clinical utility in hospitalized patients, elderly patients, immunocompromised hosts, and those with severe or worsening disease regardless of symptom duration.3 Current guidelines from the Centers for Disease Control and Prevention (CDC) recommend antiviral treatment for all hospitalized patients with confirmed or suspected influenza, all patients with severe or progressive illness, and high-risk outpatients regardless of duration of illness, while acknowledging that early initiation maximizes benefit in the outpatient ambulatory setting.
Neuraminidase inhibitors (oseltamivir, zanamivir, peramivir) are active against both influenza A and B. Baloxavir is active against both A and B. Adamantanes (amantadine, rimantadine) target the M2 ion channel, which influenza B lacks entirely — adamantanes have no activity against influenza B. Additionally, circulating influenza A H3N2 and pandemic H1N1 (2009 variant) strains carry near-universal adamantane resistance (S31N mutation in M2), making adamantanes clinically obsolete for influenza treatment.
Neuraminidase inhibitors remain the most widely used class of influenza antivirals globally, with oseltamivir (oral) and zanamivir (inhaled) representing the two agents most frequently encountered in clinical practice. Their shared mechanism — competitive inhibition of the neuraminidase active site — is exploited with structurally distinct molecules that confer different pharmacokinetic profiles and different patterns of resistance.
Mechanism of Action. Neuraminidase inhibitors are transition-state analogues that competitively bind to the conserved catalytic site of the influenza neuraminidase enzyme, blocking cleavage of sialic acid residues from glycoprotein receptors on the surface of infected cells and mucus. Without neuraminidase activity, newly assembled virions remain tethered to the surface of infected cells by uncleaved sialic acid linkages and aggregate into large viral clusters rather than dispersing through the respiratory tract. The neuraminidase active site contains eight conserved catalytic residues and eleven conserved framework residues that are structurally essential for enzyme function; drug-resistant mutations in these conserved positions typically impose substantial fitness costs on the virus, which limits their spread under natural transmission conditions.2 Oseltamivir carboxylate and zanamivir achieve equivalent inhibitory potency against neuraminidases from both influenza A and B viruses in vitro, though clinical data suggest slightly reduced efficacy of oseltamivir against influenza B compared with influenza A, possibly due to pharmacokinetic rather than pharmacodynamic differences.
Oseltamivir: Pharmacokinetics and Clinical Use. Oseltamivir phosphate is an ethyl ester prodrug that is hydrolyzed to oseltamivir carboxylate, the active neuraminidase inhibitor, primarily by hepatic carboxylesterase 1 (CES1). Oral bioavailability of the prodrug is approximately 80%, with conversion to the active form reaching approximately 75% of the administered dose systemically. Oseltamivir carboxylate is renally eliminated with a half-life of six to ten hours; dose reduction is required for creatinine clearance (CrCl) below 30 mL per minute (standard dose: 75 mg twice daily for five days treatment, 75 mg once daily for prophylaxis).4 The drug distributes to the respiratory tract at concentrations adequate for neuraminidase inhibition; lung concentrations approximate plasma levels. In healthy adults presenting within 48 hours of symptom onset, oseltamivir reduces median illness duration by approximately 17 hours in meta-analyses, with a more robust effect on prevention of lower respiratory tract complications including pneumonia and hospitalization in high-risk populations.3 For severe or complicated influenza in hospitalized patients, the standard treatment duration of five days may be extended based on clinical response and viral shedding.
Zanamivir: Inhaled Delivery and Special Populations. Zanamivir is a highly polar molecule with negligible oral bioavailability that is administered by oral inhalation using a breath-activated dry powder inhaler (Diskhaler device). Approximately 10% to 20% of the inhaled dose reaches the lungs directly, achieving high local drug concentrations at the site of infection while limiting systemic exposure to approximately 10% to 20% of the inhaled dose. Systemic zanamivir is excreted unchanged by the kidneys and does not require dose adjustment for renal impairment. The inhaled delivery route makes zanamivir pharmacokinetically unsuitable for patients with underlying airway disease, as bronchospasm has been reported, particularly in patients with asthma or chronic obstructive pulmonary disease (COPD); oseltamivir is preferred in this population. Intravenous zanamivir has been used investigationally for severe influenza in patients unable to take oral oseltamivir, particularly in cases of oseltamivir-resistant influenza or patients with malabsorption.5 Peramivir, an intravenous neuraminidase inhibitor, provides an alternative parenteral route for hospitalized patients who cannot tolerate enteral medications, administered as a single dose of 600 mg intravenously.
Neuraminidase Inhibitor Resistance. Resistance to neuraminidase inhibitors is most commonly conferred by mutations in the neuraminidase gene that alter the drug-binding site without abolishing enzymatic activity. The H275Y (histidine-to-tyrosine substitution at position 275 of neuraminidase) mutation in N1 (N1-subtype) neuraminidase (using N2 numbering: H274Y) is the most clinically significant resistance variant, conferring high-level oseltamivir resistance while largely preserving zanamivir susceptibility because of structural differences in how the two drugs contact the enzyme active site. The H275Y mutation was responsible for the oseltamivir-resistant seasonal H1N1 (influenza A/H1N1) epidemic of 2008 to 2009, in which resistant strains spread efficiently among humans without detectable fitness deficit, demonstrating that neuraminidase inhibitor resistance can spread in the community without requiring drug selection pressure. The emergence of H275Y in pandemic influenza A/H1N1 (H1N1) strains, particularly the 2009 pandemic variant, has also been documented, primarily in immunocompromised patients receiving prolonged oseltamivir therapy.5 Cross-resistance between oseltamivir and zanamivir is partial rather than complete for most clinically encountered neuraminidase (NA) mutations, making zanamivir or intravenous peramivir viable rescue options for oseltamivir-resistant influenza.
Children ≥1 year: weight-based dosing (30 mg BID if <15 kg; 45 mg BID if 15-23 kg; 60 mg BID if 23-40 kg; 75 mg BID if >40 kg) × 5 days. Neonates (0-11 months): 3 mg/kg BID. Renal: CrCl 30-60 mL/min → 30 mg BID; CrCl 10-30 mL/min → 30 mg daily; hemodialysis → 30 mg after each session. Prophylaxis dose is half the treatment dose.
Baloxavir marboxil represents the first influenza antiviral with a mechanism entirely distinct from neuraminidase inhibition to reach widespread clinical use, targeting a conserved viral enzyme at the earliest stage of viral replication inside the host cell nucleus. Its single-dose oral regimen and activity against neuraminidase inhibitor-resistant strains have positioned it as an important addition to the influenza antiviral armamentarium.
Mechanism: Cap-Dependent Endonuclease Inhibition. Baloxavir marboxil is an oral prodrug hydrolyzed by arylacetamide deacetylase in intestinal epithelium and plasma to baloxavir acid, the active inhibitor. Baloxavir acid binds to the polymerase acidic protein (PA) subunit of the influenza ribonucleic acid (RNA)-dependent RNA polymerase (RdRp) complex and specifically inhibits its cap-dependent endonuclease (CEN) activity. The CEN domain of PA cleaves the 5'-capped oligonucleotides from host pre-messenger RNA (mRNA) that are used to prime viral mRNA synthesis — a process called cap-snatching that is essential for transcription of all influenza viral genes. By blocking this initiation step, baloxavir halts production of all influenza viral proteins simultaneously, providing a mechanistic rationale for its activity against strains resistant to neuraminidase inhibitors (which act at a completely different step in the replication cycle) and against the adamantanes (which target ion channel function).6 The CEN active site contains two divalent metal ions (magnesium or manganese) coordinated by conserved active-site residues that baloxavir acid chelates through its catechol moiety.
Clinical Efficacy and Pharmacokinetics. Baloxavir marboxil is administered as a single oral dose of 40 mg for patients weighing 40 to 80 kg and 80 mg for patients weighing 80 kg or more, making it the first single-dose oral influenza treatment. The long plasma half-life of baloxavir acid (approximately 79 hours) supports this dosing strategy. The CAPSTONE-1 (Baloxavir Clinical Phase 3 Study 1) trial demonstrated that a single dose of baloxavir reduced median time to alleviation of influenza symptoms by 26.5 hours compared with placebo in otherwise healthy adults, with a magnitude of effect comparable to five days of oseltamivir; CAPSTONE-2 (Baloxavir Clinical Phase 3 Study 2) extended these findings to high-risk populations including elderly patients and those with comorbidities, demonstrating reduction in influenza-associated complications.7 The drug is active against both influenza A and B viruses and retains full activity against oseltamivir-resistant strains carrying the H275Y (histidine-to-tyrosine at position 275) neuraminidase mutation. Baloxavir is FDA-approved for treatment of acute uncomplicated influenza in patients aged five years and older who have been symptomatic for no more than 48 hours, and for post-exposure prophylaxis in patients aged five years and older.
Resistance: PA Substitutions at Position 38. The principal resistance mechanism to baloxavir involves substitutions at position 38 of the polymerase acidic protein subunit (PA-I38): PA-I38T (isoleucine-to-threonine), PA-I38F (isoleucine-to-phenylalanine), and PA-I38M (isoleucine-to-methionine), which reduce the binding affinity of baloxavir acid for the CEN active site. These substitutions emerge during treatment in a proportion of patients — approximately 2% to 9% in clinical trials in adults, rising to 23% in pediatric patients in some studies — and are associated with prolonged viral shedding and slower symptom resolution in those patients who develop them.7 The I38T substitution is the most commonly observed variant and confers the greatest reduction in susceptibility. Of note, baloxavir-resistant PA-I38 variant strains retain full susceptibility to neuraminidase inhibitors, providing a therapeutic alternative if resistance is suspected. The clinical significance of treatment-emergent resistance is still being characterized; whether these position-38 PA variants spread efficiently in the community under natural transmission conditions remains under active surveillance.
Single dose (baloxavir) vs. 10 doses over 5 days (oseltamivir): adherence advantage for baloxavir in outpatients. Both reduce duration by ~1 day in healthy adults. Baloxavir active against oseltamivir-resistant strains; oseltamivir active against baloxavir-resistant strains. Combination baloxavir + oseltamivir is under investigation for severe influenza and pandemic preparedness. Baloxavir not recommended in pregnancy (limited data); oseltamivir is preferred in pregnancy.
The adamantane antiviral agents — amantadine and rimantadine — were the first licensed influenza antivirals and for decades the only oral agents available for influenza prophylaxis and treatment. Their near-complete loss of clinical utility against contemporary influenza A strains due to widespread resistance is a paradigmatic example of how antiviral resistance can render an entire drug class obsolete within a generation of widespread use.
Mechanism: Matrix Protein 2 Ion Channel Blockade. Amantadine and rimantadine are adamantane derivatives that block the M2 (matrix protein 2) proton-selective ion channel of influenza A viruses. The M2 channel is a homotetrameric integral membrane protein that spans the viral lipid envelope and mediates proton influx into the virion interior during endosomal acidification, a step required for dissociation of the viral matrix protein (M1) from the ribonucleoprotein complexes and release of viral ribonucleic acid (RNA) into the cytoplasm. Adamantanes bind within the M2 channel pore at a site formed by residues in the transmembrane domain, physically obstructing proton conductance and preventing the pH-dependent uncoating step required for viral RNA release. Because influenza B viruses possess a structurally distinct ion channel protein (BM2) with a different pore architecture, adamantanes have no significant activity against influenza B viruses.1 At higher concentrations, amantadine also inhibits a later stage of viral assembly by preventing transport of hemagglutinin to the cell surface, though this secondary effect is not clinically relevant at standard doses.
Resistance and Current Clinical Obsolescence. Resistance to adamantanes is conferred by single-amino-acid substitutions at positions 26, 27, 30, 31, or 34 within the M2 transmembrane domain, with the serine-to-asparagine substitution at position 31 (S31N) being by far the most prevalent. The S31N mutation disrupts adamantane binding by altering the geometry of the channel pore without significantly impairing M2 proton channel function, imposing minimal fitness cost on the virus. In 2005 to 2006, adamantane resistance in circulating influenza A/H3N2 (H3N2) strains increased from approximately 2% to 96% in a single influenza season in the United States and internationally, driven primarily by rapid spread of a single resistant clade rather than de novo mutation under drug pressure. The 2009 pandemic influenza A strain (pandemic H1N1) also carries the S31N mutation and is universally adamantane-resistant. As of current surveillance data, essentially all circulating human influenza A H3N2 and pandemic H1N1 (2009 variant) strains carry adamantane resistance, rendering amantadine and rimantadine clinically obsolete for influenza treatment or prophylaxis in contemporary practice.5 Current CDC and Infectious Diseases Society of America (IDSA) guidelines do not recommend adamantanes for influenza treatment or prophylaxis due to universal resistance.
Pharmacology and Retained Non-Influenza Uses. Amantadine is well absorbed orally, distributes widely including into the central nervous system (CNS), and is excreted unchanged by the kidneys with a half-life of 10 to 28 hours; substantial dose reduction is required for renal impairment, and the drug accumulates to toxic concentrations in severe renal failure. CNS adverse effects — including insomnia, dizziness, difficulty concentrating, anxiety, and at high concentrations delirium and seizures — reflect amantadine's activity as an N-methyl-D-aspartate (NMDA) receptor antagonist and dopamine agonist/reuptake inhibitor at the level of the basal ganglia. These dopaminergic and glutamate antagonist properties underlie amantadine's retained clinical utility as a treatment for Parkinson's disease, drug-induced extrapyramidal symptoms, and fatigue in multiple sclerosis, and as an adjunctive agent in disorders of consciousness following acquired brain injury.8 Rimantadine differs from amantadine in having greater hepatic metabolism, producing lower CNS drug concentrations and fewer neurological adverse effects; it was therefore preferred over amantadine for influenza prophylaxis when adamantanes remained clinically relevant, though it shares universal antiviral resistance.
Amantadine and rimantadine should not be prescribed for influenza treatment or prophylaxis. Current circulating influenza A H3N2 and pandemic H1N1 (2009 variant) strains are universally adamantane-resistant (S31N in M2). Adamantanes have no activity against influenza B. Use oseltamivir, zanamivir, peramivir, or baloxavir for influenza. Amantadine retains legitimate indications in Parkinson disease, extrapyramidal symptoms, and disorders of consciousness — these non-antiviral uses are unaffected by M2 resistance mutations.
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in infants and young children globally and an increasingly recognized cause of serious respiratory illness in older adults and immunocompromised patients. The pharmacological armamentarium for RSV has expanded substantially in recent years with the introduction of novel monoclonal antibodies and the first RSV-specific small molecule antiviral agents, transforming a field that for decades relied almost entirely on a single modestly effective prophylactic antibody.
RSV Biology and Antiviral Targets. Respiratory syncytial virus is an enveloped, negative-sense, single-stranded ribonucleic acid (RNA) virus of the family Pneumoviridae, genus Orthopneumovirus, and is classified into two major antigenic groups, RSV-A (respiratory syncytial virus group A) and RSV-B (respiratory syncytial virus group B), both of which circulate annually. The two major RSV surface glycoproteins — the fusion protein (F protein) and the attachment glycoprotein (G protein) — are the principal targets of neutralizing antibody responses and antiviral drugs. The F protein mediates viral membrane fusion by undergoing a dramatic conformational change from its metastable prefusion state to a stable postfusion conformation; this irreversible structural transition drives fusion of the viral envelope with the host cell plasma membrane. Antibodies that bind the prefusion conformation of the F protein are substantially more potent neutralizers than those targeting the postfusion conformation, a discovery that substantially reshaped RSV vaccine and monoclonal antibody development.9 The ribonucleoprotein complex, including the RNA-dependent RNA polymerase, provides additional therapeutic targets currently being exploited by small molecule antivirals in clinical development.
Ribavirin: Mechanism and Current Role. Ribavirin is a synthetic nucleoside analogue of guanosine with broad-spectrum antiviral activity against both RNA and deoxyribonucleic acid (DNA) viruses. Its mechanisms of action are multiple and incompletely understood but include competitive inhibition of the inosine monophosphate dehydrogenase (IMPDH) enzyme, which depletes intracellular guanosine triphosphate (GTP) pools and impairs viral RNA synthesis; direct inhibition of viral RNA-dependent RNA polymerases; and viral mutational catastrophe through lethal mutagenesis, whereby ribavirin's incorporation into viral RNA introduces an excess of mutations that extinguish viable viral populations. Inhaled ribavirin (aerosol administration via small-particle aerosol generator, SPAG-2 device) was licensed for treatment of RSV bronchiolitis in hospitalized infants in 1986, but evidence of clinical benefit has remained weak in randomized controlled trials, and its use has declined substantially. Current practice reserves aerosolized ribavirin for immunocompromised patients with severe RSV lower respiratory tract disease — particularly hematopoietic stem cell transplant (HSCT) recipients — where observational data suggest potential benefit in reducing progression to respiratory failure, often combined with intravenous immunoglobulin (IVIG) or RSV-specific monoclonal antibodies.10 Ribavirin is teratogenic and embryotoxic in animal models; healthcare workers of childbearing potential require respiratory protection during administration of aerosolized ribavirin.
Palivizumab and Nirsevimab: Prophylactic Monoclonal Antibodies. Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the A antigenic site of the RSV F protein that prevents viral membrane fusion by sterically blocking the conformational change required for membrane fusion. Monthly intramuscular injections of palivizumab (15 mg per kilogram) during RSV season reduce RSV hospitalization rates by approximately 55% in premature infants and infants with hemodynamically significant congenital heart disease or chronic lung disease of prematurity — the populations for whom it is licensed. Nirsevimab (Beyfortus), approved in 2023, represents a major advance over palivizumab: it is a long-acting monoclonal antibody engineered with an extended-half-life Fc region that targets a prefusion-specific epitope (antigenic site II/IV) on the RSV F protein, providing protection for an entire RSV season with a single intramuscular injection rather than monthly dosing. Nirsevimab demonstrated approximately 74% to 83% efficacy in preventing RSV-associated lower respiratory tract infection requiring medical attention in clinical trials across multiple infant populations, including both premature and full-term infants, and is now recommended by the Advisory Committee on Immunization Practices (ACIP) for all infants under eight months entering their first RSV season.9
Nirsevimab (single injection, all infants under 8 months entering first RSV season) has largely replaced palivizumab for RSV prophylaxis. Palivizumab (monthly injections, 5 doses per season) is now reserved for high-risk groups: gestational age ≤28 weeks (first year), chronic lung disease of prematurity requiring medical therapy, or hemodynamically significant congenital heart disease. RSV vaccines for maternal immunization (Abrysvo) and older adults (Abrysvo, Arexvy) are now licensed and provide additional prevention strategies in non-infant populations.
The coronavirus disease 2019 (COVID-19) pandemic accelerated antiviral drug development for respiratory viruses on an unprecedented scale, producing new small molecule antivirals and monoclonal antibodies whose mechanisms and resistance patterns illuminate general principles applicable across the respiratory virus pharmacology landscape. Understanding these emerging agents and the resistance dynamics they generate equips the clinician to navigate a rapidly evolving therapeutic field.
Nirmatrelvir-Ritonavir: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Main Protease Inhibition. Nirmatrelvir-ritonavir (Paxlovid) is an oral antiviral combination approved for treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults at high risk of progression to severe disease. Nirmatrelvir is a peptidomimetic inhibitor of the SARS-CoV-2 main protease (Mpro, also designated 3CLpro), which cleaves the viral polyprotein precursors into functional nonstructural proteins required for viral replication. Mpro inhibition blocks processing of the replicase polyprotein, halting viral ribonucleic acid (RNA) synthesis. Ritonavir is a pharmacokinetic booster — it inhibits cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp), substantially increasing nirmatrelvir plasma concentrations and extending its effective half-life to clinically useful levels. Drug-drug interactions involving CYP3A4 substrates are extensive and clinically critical: ritonavir coadministration can raise plasma concentrations of CYP3A4-metabolized drugs to potentially dangerous levels, including immunosuppressants (tacrolimus, cyclosporine), antiarrhythmics (amiodarone, flecainide), statins (simvastatin, lovastatin), and certain anticoagulants.11 The EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial demonstrated an 89% reduction in hospitalization or death in high-risk unvaccinated adults treated within three days of symptom onset. Rebound of COVID-19 symptoms and viral load after completion of the standard five-day course has been reported, the mechanism of which remains under investigation.
Remdesivir: Adenosine Analogue RdRp Inhibition. Remdesivir is a phosphoramidate prodrug of an adenosine analogue that is activated intracellularly to its triphosphate form, remdesivir triphosphate, which acts as an alternative substrate and delayed chain terminator for RNA-dependent RNA polymerases (RdRp) of a broad range of RNA viruses. Following incorporation into the growing RNA chain at position i, chain elongation is terminated at position i+3, four nucleotides downstream, by steric clash between the 1'-cyano group of the incorporated analogue and the RdRp active site. Remdesivir was the first antiviral approved specifically for COVID-19 (for hospitalized patients requiring supplemental oxygen) and has also been investigated for respiratory syncytial virus (RSV), Ebola, and other RNA virus infections. Its clinical benefit in COVID-19 is modest but measurable in hospitalized patients who require low-flow supplemental oxygen but have not yet progressed to mechanical ventilation; benefit in patients already requiring high-flow oxygen or mechanical ventilation is less clearly established. Remdesivir is administered intravenously (200 mg loading dose, then 100 mg daily for 4 additional days), limiting its use to hospital settings except for a high-risk outpatient three-day course approved for patients at high risk of severe COVID-19.6
General Principles of Respiratory Antiviral Resistance. RNA viruses, including influenza and coronaviruses, replicate with error-prone RNA polymerases that lack proofreading activity, generating mutation rates of approximately 10-4 to 10-6 substitutions per nucleotide per replication cycle. This high mutation rate means that every possible single-nucleotide substitution is generated many times daily within an infected host, placing preformed resistant variants in the viral quasispecies prior to drug exposure. Drug selection then amplifies resistant variants already present, rather than inducing de novo mutation. The fitness cost of resistance mutations — meaning the degree to which a given mutation impairs viral replication in the absence of drug — is the primary determinant of whether resistance spreads in the population. The adamantane serine-to-asparagine at position 31 (S31N) mutation in influenza M2 (matrix protein 2) imposes negligible fitness cost and has spread globally. The baloxavir PA-I38T (isoleucine-to-threonine at PA position 38) mutation imposes moderate fitness cost, limiting but not preventing community spread. Resistance surveillance through national and international networks such as the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) is essential for detecting emerging resistance before it becomes widespread, guiding annual antiviral prescribing recommendations.5
Ritonavir is a potent CYP3A4 inhibitor. Before prescribing: check all CYP3A4 substrates. Absolute contraindications include colchicine (in renal/hepatic impairment), lurasidone, pimozide, ranolazine, dronedarone, ergot alkaloids, triazolam, and oral midazolam. Dose-adjust or temporarily discontinue: tacrolimus (reduce dose 50-90%), cyclosporine, simvastatin/lovastatin (hold during course), warfarin (monitor INR closely), and direct oral anticoagulants (rivaroxaban, apixaban). Use the NIH COVID-19 Treatment Guidelines drug interaction checker before every prescription.
Krammer F, Smith GJD, Fouchier RAM, et al. Influenza. Nat Rev Dis Primers. 2018;4(1):3.
doi:10.1038/s41572-018-0002-yvon Itzstein M. The war against influenza: discovery and development of sialidase inhibitors. Nat Rev Drug Discov. 2007;6(12):967–974.
doi:10.1038/nrd2400Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet. 2015;385(9979):1729–1737.
doi:10.1016/S0140-6736(14)62449-1Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282(13):1240–1246.
doi:10.1001/jama.282.13.1240Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014;8:22–29.
doi:10.1016/j.coviro.2014.04.009Noshi T, Kitano M, Taniguchi K, et al. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018;160:109–117.
doi:10.1016/j.antiviral.2018.10.008Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913–923.
doi:10.1056/NEJMoa1716197Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA. 1969;208(7):1168–1170.
doi:10.1001/jama.1969.03160070058011Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837–846.
doi:10.1056/NEJMoa2110275Waghmare A, Campbell AP, Xie H, et al. Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. Clin Infect Dis. 2013;57(12):1731–1741.
doi:10.1093/cid/cit639Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–1408.
doi:10.1056/NEJMoa2118542